Randomized, Double-blind, Placebo-controlled Phase 3 Study of Ibrutinib, a Bruton s Tyrosine Kinase (BTK) Inhibitor, in Combination With Bendamustine and Rituximab (BR) in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Trial Profile

Randomized, Double-blind, Placebo-controlled Phase 3 Study of Ibrutinib, a Bruton s Tyrosine Kinase (BTK) Inhibitor, in Combination With Bendamustine and Rituximab (BR) in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 23 Nov 2017

At a glance

  • Drugs Ibrutinib (Primary) ; Bendamustine; Rituximab
  • Indications Chronic lymphocytic leukaemia
  • Focus Registrational; Therapeutic Use
  • Acronyms HELIOS
  • Sponsors Janssen Research & Development
  • Most Recent Events

    • 17 Nov 2017 Planned End Date changed from 11 Apr 2019 to 19 Jan 2019.
    • 27 Jul 2017 Planned End Date changed from 19 Jan 2019 to 11 Apr 2019.
    • 20 May 2017 According to an AbbVie media release, pooled data from three studies RESONATE, RESONATE-2 and HELIOS were presented today in an oral presentation at the 17th International Workshop on Chronic Lymphocytic Leukemia (iwCLL) biennial meeting
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top